The continuously evolving CMC regulatory landscape presents a steady challenge to the development of new drugs and biologics. For example, regulator’s expectation to adopt new paradigms of drug development (e.g. QbD/PAT) and increased testing and controls can add major CMC challenges in the current climate of globalized and outsourced R&D and manufacturing settings. The opportunity for expedited regulatory pathways pose additional CMC challenges for the timely development of a commercial ready process. These scenarios are further confounded by the lack of harmonized global regulations. At Syner-G, we have extensive experience in navigating this landscape and are passionate in helping our clients in the design, planning and execution of CMC strategies critical for the successful development and timely approval of new drugs.
Whether you seek expert regulatory advice for regulatory starting materials selection, identifying control strategies for genotoxic impurities, or help in strategizing and preparing briefing documents or CTD Modules 3 and 2 of regulatory submissions, we have qualified professionals to support your specific regulatory requirements. Our staff comes from the pharma industry and the FDA, with proven expertise in all areas of CMC Regulatory Affairs to support global clinical trials and market authorization applications. We are adept in designing phase appropriate and product specific CMC strategies that are the key to successful and expedited drug development.